Thursday, May 18, 2023 9:24:57 AM
scotty3371,
Maybe those thinking longer term would rather not waste money on clean rooms that won’t be needed for very long and are very high maintenance. Maybe product release is a bottleneck that needs to be resolved. Maybe the bigger boat has more to do with advancing Edens to accommodate future demand from an approval EVEN IF Edens is not technically “required” for approval. Maybe the thinking is more “patients first” than “penny traders first”. In other words, maybe what you want, to benefit your way of doing things just isn’t as important as what is best for patient access once an approval is granted. Maybe the goal is to have Edens ready ASAP once approval is given so that access is widely available to patients once “the process” is completed and reimbursement is in place. Hmm. Put the two in a balancing scale and see what happens. Pennies or PATIENTS.. pennies or PATIENTS, pennies or PATIENTS?; ). Best wishes.
Maybe those thinking longer term would rather not waste money on clean rooms that won’t be needed for very long and are very high maintenance. Maybe product release is a bottleneck that needs to be resolved. Maybe the bigger boat has more to do with advancing Edens to accommodate future demand from an approval EVEN IF Edens is not technically “required” for approval. Maybe the thinking is more “patients first” than “penny traders first”. In other words, maybe what you want, to benefit your way of doing things just isn’t as important as what is best for patient access once an approval is granted. Maybe the goal is to have Edens ready ASAP once approval is given so that access is widely available to patients once “the process” is completed and reimbursement is in place. Hmm. Put the two in a balancing scale and see what happens. Pennies or PATIENTS.. pennies or PATIENTS, pennies or PATIENTS?; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
